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Abstract 
Background: HLA class I-associated escape mutations in HIV-1 Gag can reduce viral replication, suggesting that 
associated fitness costs could impact HIV-1 disease progression. Previous studies in North American and African 
cohorts have reported reduced Gag-Protease mediated viral replication capacity (Gag-Pro RC) in individuals express-
ing protective HLA class I alleles including HLA-B*57:01, B*27:05, and B*81:01. These studies also reported significant 
positive associations between Gag-Pro RCs and plasma viral load (pVL). However, these HLA alleles are virtually absent 
in Japan, and the importance of Gag as an immune target is not clearly defined in this population.
Results: We generated chimeric NL4-3 viruses carrying patient-derived Gag-Protease from 306 treatment-naive Japa-
nese individuals chronically infected with HIV-1 subtype B. We analyzed associations between Gag-Pro RC and clinical 
markers of HIV-1 infection and host HLA expression. We observed no significant correlation between Gag-Pro RC and 
pVL in Japan in the overall cohort. However, upon exclusion of individuals expressing Japanese protective alleles HLA-
B*52:01 and B*67:01, Gag-Pro RC correlated positively with pVL and negatively with CD4 T-cell count. Our results thus 
contrast with studies from other global cohorts reporting significantly lower Gag-Pro RC among persons expressing 
protective HLA alleles, and positive relationships between Gag-Pro RC and pVL in the overall study populations. We 
also identified five amino acids in Gag-Protease significantly associated with Gag-Pro RC, whose effects on RC were 
confirmed by site-directed mutagenesis. However, of the four mutations that decreased Gag-Pro RC, none were asso-
ciated with reductions in pVL in Japan though two were associated with lower pVL in North America.
Conclusions: These data indicate that Gag fitness does not affect clinical outcomes in subjects with protective HLA 
class I alleles as well as the whole Japanese population. Moreover, the impact of Gag fitness costs on HIV-1 clinical 
parameters in chronic infection is likely low in Japan compared to other global populations.
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Background
Within an infected individual, immune pressure by cyto-
toxic T lymphocytes (CTLs) induces the selection of 
HLA-associated escape variants in the HIV-1 genome. 
The persistence of HLA-associated escape variants upon 
transmission in turn shapes viral diversity at the popula-
tion level [1]. CTL escape occurs throughout infection. 
Moreover, certain escape mutations compromise viral 
fitness. In some of these cases, their effects on immune 
evasion can be offset in part by their fitness costs though 
the effects of such mutations on plasma viral load (pVL) 
are complex and remain incompletely understood [2–9]. 
HIV-1 Gag is rich in immunodominant CTL epitopes, 
and a vital role of anti-Gag CTL responses on HIV-1 
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immune control has been demonstrated [10, 11; also 
reviewed in 12, 13]. In particular, associations between 
fitness-costly Gag escape mutations and decreases in pVL 
have been described [2, 5–8], notably for the immuno-
dominant HLA-B*57:01-restricted TW10 and B*27:05-
restricted KK10 epitopes, both of which are well studied 
because of their protective roles in HIV-1 disease out-
come. Specifically, CTL-driven escape mutations in 
TW10 impose a mild fitness cost that, along with robust 
HLA-B*57:01-driven CTL responses, likely contribute 
to the significantly lower pVL observed in these subjects 
[5, 7, 14–17]. Notably however, fitness costs of escape 
in HLA-B*57:01 epitopes are generally rescued by the 
subsequent appearance of compensatory mutations [18, 
19]. In contrast, a single amino acid change at Gag 264 
(R264K) in the B*27:05-restricted KK10 epitope substan-
tially compromises in vitro viral replication [20–22], but 
this mutation generally occurs late in infection due to the 
requirement for the upstream compensatory mutation 
S173A [7, 21]. As such, the appearance of R264K in vivo 
generally heralds HIV-1 progression [23, 24]. These stud-
ies support a relationship between Gag escape mutations 
and pVL and underscore a critical role of Gag in HIV-1 
disease outcome.
In vitro studies also highlight the importance of Gag as 
an immune target. Certain HLA-associated mutations in 
Gag have been shown to impair Gag-Protease-mediated 
viral replication capacity in vitro (Gag-Pro RC). Gag-Pro 
RC is in turn positively associated with pVL in numer-
ous global cohorts [18, 25–30]. In particular, reduced 
Gag-Pro RC has been observed in predominantly North 
American cohorts of elite controllers as well as individu-
als in acute/early infection who express protective alleles 
B*13, B*27, B*57, and/or B*58:01 [18, 26], though the 
latter associations are less apparent during the chronic 
phase [18]. In addition, the impact of HLA-associated 
changes in Gag-Pro RC on pVL have also been reported in 
African cohorts chronically infected with HIV-1 subtype 
C [27–29]. A more recent study compared Gag-Pro RCs 
in treatment-naive Mexican and Barbadian HIV-1 sub-
type B cohorts which differ in their frequency of protec-
tive HLA alleles (8 % versus 34 % of B*27/57/58:01/81:01 
in Mexico versus Barbados). The study revealed a higher 
burden of HLA-mediated Gag escape mutations and sig-
nificantly lower Gag-Pro RC in chronically infected Bar-
badian compared to Mexican individuals [30]. Moreover, 
Gag-Pro RC correlated positively with pVL, supporting 
the importance of Gag in HIV-1 disease outcome [30]. 
The significantly lower Gag-Pro RC and pVL in Barbados 
versus Mexico was attributed to the higher prevalence 
of protective HLA alleles in the former cohort, implying 
that protective alleles lower Gag-Pro RC, viral set points, 
and therefore, disease progression rates at the population 
level. These results are consistent with a previous study of 
nine distinct cohorts worldwide that demonstrates HIV-1 
adaptation to HLA class I alleles at a population level, 
presumably as a result of transmission and persistence 
of certain escape mutations in the population [1]. Thus, 
HLA allele frequency shapes viral diversity, which could 
also affect CTL responses and HIV-1 disease outcome in 
the population.
HLA class I distributions differ markedly in Asian com-
pared with North American and African cohorts [31]. 
The “classical” protective alleles B*27:05 and B*57:01 
are essentially absent in Japan: a published cohort of 
504 treatment-naive HIV+ Japanese featured only one 
B*27:05+ and no B*57:01 patients [31–37]. Instead, 
B*52:01 and B*67:01 are associated with HIV-1 control 
in Japan [32]. Therefore, the role of Gag fitness in HIV-1 
pathogenesis, or more broadly the mechanism of pro-
tection, is likely to be different in Asian populations. As 
such, the impact of HLA-mediated immune pressure 
on viral fitness and its influence on HIV-1 pathogenesis 
need to be specifically defined for Asian populations. To 
address these issues, we investigated the effect of HLA-
associated changes in Gag-Pro RC in 306 treatment-naive 
HIV+ Japanese patients chronically infected with HIV-1 
subtype B in the presence or absence of protective HLA 
alleles. We also identified amino acid changes in Gag-
Protease that altered Gag-Pro RCs and examined their 
associations with pVL. In contrast to studies of non-
Asian cohorts that supported a role of Gag fitness in 
HIV-1 disease outcome, our results suggested that Japa-
nese protective alleles did not lower Gag-Pro RC and that 
Gag fitness did not correlate with clinical markers in the 
whole Japanese population.
Results
Relationship between Gag‑Protease‑dependent replication 
capacity and clinical markers of disease progression
We generated recombinant HIV-1NL4-3 containing Gag-
Protease from 306 treatment-naïve Japanese subjects 
chronically infected with HIV-1 subtype B. Plasma viral 
sequences were determined for all patients in a previ-
ous study [31], and the patient origin of all recombinant 
viruses was confirmed by maximum likelihood phyloge-
netic analysis (Additional file  1). Recombinant viruses 
were used to infect a reporter CD4+ T-cell line, CEM-
GXR, which naturally expresses CXCR4 and has been 
further engineered to express CCR5 and Tat-inducible 
GFP [38]. Gag-Protease-dependent replication capacities 
(Gag-Pro RCs) were determined based on the exponen-
tial increase in the  % GFP+ cells during days 2–8 follow-
ing infection and normalized against that of the parental 
HIV-1NL4-3 as described for North American and African 
studies [18, 25–30]. Similar to previous reports, Gag-Pro 
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RCs were normally distributed (Fig. 1a), with a mean of 
1.12, a standard deviation (SD) of 0.13, and a range of 
0.67–1.56. The mean Gag-Pro RC in the Japanese cohort 
was slightly higher than that observed in the North 
American cohort [18] but comparable to those reported 
more recently for an ART-naïve Mexican cohort [30].
To examine the impact of Gag-Pro RC on HIV-1 patho-
genesis, we investigated the relationship between Gag-
Protease RC and clinical markers of HIV-1 infection (pVL 
and CD4 T-cell count). Overall, Japanese Gag-Pro RCs 
did not correlate with pVL (R = 0.092, P = 0.11; Fig. 1b) 
nor CD4 T-cell count (R = −0.078, P = 0.17; Fig. 1c). Not 
only did these results not achieve statistical significance, 
but the correlation coefficients for pVL and Gag-Pro RC 
in Japan were weaker than those reported in African 
(R  =  0.24) [28, 29] and Mexican/Barbadian (R  =  0.25) 
[30] chronic cohorts. The Japanese correlation coefficient 
R =  0.092 was also weaker to that reported in a North 
American chronic cohort (R  =  0.27 in the presence of 
protective HLA alleles; R = 0.12 for the total population) 
[18]. Together, this result suggested a minimal role for 
Gag fitness as a major determinant of virologic control in 
Japan compared to other global cohorts.
Impact of HLA class I alleles on Gag‑Pro RCs 
and relationship with clinical parameters
To investigate the role of Gag as an HLA-mediated 
immune target, we stratified HLA class I alleles based on 
their median RCs (Additional file  2A-C). For all alleles 
with frequencies >3 % (n > 8) in the cohort, we did not 
Fig. 1 Gag-mediated replication capacities in a treatment naive Japanese cohort chronically infected with HIV-1 subtype B. a Distribution of Gag-
Protease replication capacities. Recombinant HIV-1NL4-3 was constructed, using plasma-derived gag-protease from treatment-naïve HIV
+ Japanese 
patients, and replication capacity for each virus was determined by in vitro infection. The values were normalized against mean growth rate of wild-
type NL4-3. The samples were measured in triplicate. b, c Replication capacities and patients’ clinical parameters. Replication capacities of chimeric 
viruses were plotted against plasma viral load (b) or CD4 count (c) at the time of sample collection. Correlations were determined by Spearman’s 
rank correlation test
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find any significant associations between HLA alleles and 
Gag-Pro RC. In addition, for each HLA allele, we com-
pared the relative rankings of median RCs amongst the 
HLA alleles with those previously determined for pVL 
[32]. If Gag-Pro RC affects pVL, HLA alleles with lower 
Gag-Pro RCs would show a tendency toward lower 
pVL and vice versa. However, the relative RC ranking 
(in Additional file  2A-C) and pVL for each HLA allele 
did not match in most cases. We previously reported 
that A*33:03, B*44:03, B*40:06, C*14:03, and C*12:02 
were associated with lower pVL in Japan [32], but none 
of these alleles were associated with lower Gag-Pro RC 
(Additional file  2A-C). Notably, the median Gag-Pro 
RCs in individuals expressing Japanese protective alleles 
HLA-B*52:01 and B*67:01 [32] were higher than the pop-
ulation median (Additional file 2B), indicating that pro-
tective-allele expression is not associated with lower Gag 
fitness in Japan. Indeed, no significant correlation was 
observed between median Gag-Pro RCs and median pVL 
for each HLA allele (Additional file 2D).
To further explore the relationship between HLA, Gag-
Pro RC, and HIV-1 clinical parameters, we grouped our 
cohort by HLA-allele expression and analyzed associa-
tions between Gag-Pro RCs and HIV-1 clinical param-
eters in each HLA group (Table 1). In two HLA-A alleles 
(A*02:01 and A*31:01), one B allele (B*07:02), and two C 
alleles (C*08:01 and C*08:03), Gag-Pro RC exhibited a 
positive correlation with pVL (p < 0.05), whereas Gag-Pro 
RC exhibited negative correlations with CD4 count at this 
threshold in seven alleles (HLA-A*02:06, HLA-B*46:01, 
B*48:01, B*59:01, C*01:02, C*08:01, and C*08:03; Table 1). 
However, only in HLA-C*08:01+ (n = 34) and C*08:03+ 
(n = 10) subjects, Gag-Pro RC correlated with both clini-
cal parameters: a positive correlation with pVL (R = 0.36 
and R  =  0.70, respectively) and an inverse correlation 
with CD4 count (R = −0.46 and R = −0.69, respectively; 
Fig. 2). 
We also examined groups of patients based on non-
expression of particular HLA alleles. We observed 
significant correlations between clinical parameters 
and Gag-Pro RCs in the absence of eight HLA alleles 
(Table  1), including HLA-B*52:01. In individuals lack-
ing the Japanese protective B*52:01 allele, Gag-Pro RCs 
correlated positively with pVL (R  =  0.15, P  =  0.021, 
q = 0.24, n = 234) and inversely with CD4 T-cell count 
(R = −0.19, P = 0.005, q = 0.16; Fig. 2). Similarly, Gag-
Pro RC also showed significant associations with both 
pVL and CD4 count in individuals lacking HLA-C*12:02 
(Fig.  2). HLA-B*52:01 and C*12:02 form a haplotype in 
Japan [31–36]. Indeed, all B*52:01+ subjects had C*12:02, 
and of 85 C*12:02+ subjects in our cohort, only three did 
not carry B*52:01. Positive correlations between Gag-Pro 
RC and pVL were additionally observed in the absence of 
A*11:01, A*33:03, B*39:01, B*44:03, C*07:02, and C*14:03 
(Table 1), but none of these alleles associated with CD4 
count. Taken together, our results stand in contrast to 
observations of lower Gag-Pro RC among individuals 
expressing classical protective HLA alleles in other global 
cohorts [18, 25–30]. HIV-1 control by protective HLA 
alleles is not associated with low Gag fitness in Japan.
Table 1 Associations of Gag-Pro RCs with clinical parameters in each HLA class I allele
Italic HLA alleles have associations with both pVL and CD4 count
n number of subjects, R Spearman’s rank correlation
a HLA+ and HLA− indicate subjects with or without the particular HLA allele, respectively
Associations with pVL Associations with CD4 count
HLA allele HLA + or −a n R P value q value HLA allele HLA + or −a n R P value q value
A*02:01 + 63 0.26 0.0428 0.243 A*02:06 + 61 −0.29 0.0231 0.279
A*31:01 + 48 0.31 0.0357 0.238 B*46:01 + 31 −0.41 0.0264 0.279
B*07:02 + 24 0.46 0.0288 0.238 B*48:01 + 14 −0.65 0.0194 0.279
C*08:01 + 34 0.36 0.0377 0.238 B*59:01 + 14 −0.59 0.0344 0.318
C*08:03 + 10 0.70 0.0365 0.238 C*01:02 + 92 −0.28 0.0082 0.163
A*11:01 − 252 0.14 0.0277 0.238 C*08:01 + 34 −0.46 0.0088 0.163
A*33:03 − 265 0.14 0.0288 0.238 C*08:03 + 10 −0.69 0.0399 0.328
B*39:01 − 285 0.12 0.0385 0.238 B*52:01 − 234 −0.19 0.0045 0.163
B*44:03 − 266 0.14 0.0244 0.238 C*12:02 − 231 −0.20 0.0024 0.163
B*52:01 − 234 0.15 0.0209 0.238
C*07:02 − 233 0.14 0.0325 0.238
C*12:02 − 231 0.16 0.0135 0.238
C*14:03 − 267 0.14 0.0251 0.238
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Impact of Gag on clinical parameters in the absence 
of protective alleles
In our cohort, Gag-Pro RCs did not correlate with pVL 
in subjects carrying either of the Japanese protec-
tive alleles, B*52:01 or B*67:01. However, exclusion 
of B*52:01 (n  =  234) resulted in associations of Gag-
Pro RCs with clinical markers of infection (R  =  0.15, 
P = 0.021, q = 0.24 for pVL; Table 1). Therefore, we next 
examined correlations between Gag-Pro RCs and clini-
cal parameters in the absence of these protective alleles 
(i.e. among B*52:01 and B*67:01 double-negative sub-
jects; n = 224). In persons lacking both of these protec-
tive alleles, Gag-Pro RCs exhibited a positive association 
with pVL (R = 0.16, P = 0.017) and a negative association 
with CD4 count (R = −0.21, P = 0.0019) (Fig. 3a). These 
associations are weaker than those observed in Mexi-
can/Barbadian, African, and North American individu-
als expressing protective HLA alleles (R  >  0.2 for these 
cohorts) but comparable in magnitude to the relation-
ship between Gag-Pro RC and pVL in the North Ameri-
can chronic cohort (R =  0.12, P =  0.0007) [18, 29, 30]. 
Indeed, after excluding B*52/B*67/C*12 alleles, the asso-
ciations of Gag-Pro RC and clinical parameters became 
slightly stronger in each HLA allele- group analyzed in 
Table  1 (Additional file  3). These observations further 
support our result that Gag fitness does not associate 
with clinical parameters in subjects with protective HLA 
alleles in Japan.
When we further explored the relationship between 
Gag-Pro RC and HIV clinical parameters in the 
B*52:01−B*67:01− subpopulation by multivariable 
analyses, a linear regression model adjusting for pVL 
and CD4 count indicated that Gag-Pro RC in this sub-
set was driven largely by CD4 count (P = 0.043; β Esti-
mate  =  −0.012  per  100  cell/mm3 increment) and not 
pVL (P = 0.47; β Estimate = 0.0091 per log10 increment). 
In other words, the model indicated that, after control-
ling for pVL, Gag-Pro RC decreased by 0.012 units for 
each increment of 100  CD4  cells/mm3. Although the 
model identified CD4 count as an independent predictor 
of Gag-Pro RC, CD4 count explains only 3.7 % of popula-
tion variation in Gag-Pro RC (Table 2). In another linear 
regression model additionally incorporating three HLA 
alleles—C*08:01, C*08:03, and C*12:02—that exhibited 
significant associations of Gag-Pro RC with both pVL 
and CD4 count in the B*52:01−B*67:01− subpopulation, 
the addition of HLA information to the model did not 
improve the model fit (P = 0.12). Taken together, results 
of the multivariable analyses suggest that apparent HLA 
associations with Gag-Pro RC, HIV clinical parameters, 
Fig. 2 Replication capacities for HLA alleles and their associations with clinical parameters. The presence (HLA-C*08:01 and C*08:03) or absence 
(HLA-B*52:01 and C*12:01) of four HLA alleles showed significant associations with pVL (top panels) as well as CD4 count (bottom panels). The asso-
ciations were examined by Sperman’s rank correlation test
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and HLA alleles are likely to be driven primarily by CD4 
count rather than pVL in subjects lacking the protective 
B*52 and B*67 alleles. Moreover, these observations raise 
the possibility that Gag-Pro RC may not have a major 
impact on pVL even in the B*52−B*67− subpopulation.
We next analyzed the impact of HLA associated poly-
morphisms on pVL in 218 B*52:01− B*67:01− subjects 
based on the HLA associated polymorphisms deter-
mined for the Japanese population [31]. Here, HLA-
associated polymorphisms were defined based on a 
published list derived from plasma virus sequences 
from the present cohort (see methods and [31]; these 
Fig. 3 The relationship between HLA-associated-polymorphisms and Gag-Protease-mediated replication capacities in the HLA-B*52:01−B67:01− 
population. a Associations of replication capacities with plasma viral load and CD4 count in the B*52:01−B*67:01− population were tested by Spear-
man’s rank correlation test. b–g An overall number of HLA-induced mutations in Gag (b), Protease (c), and both regions (d) were plotted against 
Gag-Protease-mediated replication capacities to assess their impact on viral fitness. Their effects on patients’ plasma viral load were also tested 
statistically (e–g)
Table 2 Linear regression models investigating the rela-
tionship between Gag-Pro RC and clinical factors (analysis 
limited to individuals lacking B*52/B*67)
β Estimates for log10viral load are expressed per log10 increment. Estimates for 
CD4 count are expressed per 1 cell/mm3 increment
a Model: multiple r2 = 0.037, P = 0.015
Variable Multivariable linear regression model 
parameters (Gag‑Pro RC)a
Estimate P value
Log10pVL 9.13 × 10−3 0.47
CD4 −1.16 × 10−4 0.043
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included 94 HLA-associated polymorphisms in Gag 
and 16 in Protease). For each individual in this analysis, 
we counted the number of HLA-associated polymor-
phisms present in their viral sequence (regardless of the 
host HLAs expressed). In doing so we observed no cor-
relation between the number of polymorphisms in Gag, 
Protease, or Gag-Protease and Gag-Pro RCs (Fig. 3b–d). 
On the other hand, statistically significant negative cor-
relations were observed between the number of HLA-
associated polymorphisms in Gag (R = −0.15, P = 0.024) 
as well as Gag-Protease (R = −0.16, P = 0.018) and pVL 
(Fig. 3e–g). This suggests that HLA-associated polymor-
phism burden in Gag impacts pVL without significantly 
affecting Gag-Pro RCs in the B*52−B*67− subpopulation, 
indicating the possible absence of correlation between 
Gag-Pro RC and pVL in this subpopulation. A simple 
explanation for the discrepancy would be that a combi-
natorial effect by mutations in other parts of the virus 
may have resulted in the significant change in pVL even 
though the number of polymorphisms in Gag only was 
not enough to affect Gag replication per se.
Impact of amino acid changes on Gag RCs in the absence 
of the protective alleles
We expanded our search for mutations in Gag that would 
affect Gag-Pro RCs in the B*52:01− B*67:01− subjects. In 
an exploratory analysis, we statistically identified amino 
acids in Gag that were associated with Gag-Pro RCs 
in persons lacking the protective B*52:01 and B*67:01 
alleles. We identified amino acid variants at four posi-
tions, Gag 79, 228, 286, and 357 that were associated with 
lower Gag-Pro RC and at one position, Gag 218, which 
was associated with a higher Gag-Pro RC (Table  3). To 
evaluate the potential combinatorial effects of these 
mutations on Gag-Pro RC, we assigned a score to each 
recombinant Gag-Protease viral sequence by assigning 
+1 for the presence of the RC-increasing residue and −1 
for each of the four RC-decreasing residues and com-
puting this sum. Overall, these scores exhibited a sig-
nificant positive correlation with Gag-Pro RCs (R = 0.35, 
P = 0.03 × 10−6; Fig. 4a). This suggests a dose-depend-
ent effect of these substitutions on replication capac-
ity, which we sought to confirm in vitro. To do this, we 
focused on the amino acid changes that reduced Gag-
Pro RC and introduced Gag Y79F and R286K substitu-
tions (the most frequent variations at these positions; 
Additional file 4), along with Gag M228L into pNL4-3 by 
site-directed mutagenesis. NL4-3 naturally carries gly-
cine at Gag357 and therefore naturally contains a residue 
other than S at this site (357G). Note that the combina-
tion of these four substitutions 79F+228L+286K+357G 
was observed in naturally occurring sequences from our 
cohort. The mutant NL4-3 carrying these four Gag-Pro 
RC-reducing changes exhibited 20  % decreased replica-
tion capacity compared to wild-type (P < 0.0001; Fig. 4b). 
Thus, the in vitro result confirmed the effect of the amino 
acid changes on the viral replication capacity. 
Even though the presence of these amino acid changes 
in the HLA-B*52:01−B*67:01− subpopulation reduced 
viral replication capacity in  vitro, they did not signifi-
cantly correlate with pVL in this subpopulation (Fig. 5a). 
To investigate the potential in  vivo importance of these 
amino acid changes in a non-Japanese cohort, we ana-
lyzed associations between these variants and pVL in a 
North American cohort that previously reported stronger 
positive correlations between Gag-Pro RC and pVL [18]. 
In the North American cohort, B*52:01/C*12:02 preva-
lence is <2  % and B*67:01 prevalence is 0  %, and thus 
these alleles are unlikely to influence the present analy-
sis [18]. In contrast to the Japanese cohort, the North 
American cohort showed a weak association between 
pVL and mutation scores (R = 0.078, P = 0.049; Fig. 5b), 
suggesting a minor but significant impact of these poly-
morphisms in  vivo. Individual analysis of mutations 
at each position also revealed significantly lower pVL 
among individuals harboring amino acid variants at Gag 
79 (Y79 versus non-Y) and 228 (M228L) in the North 
American cohort (Fig.  5d). In contrast, no such rela-
tionships were observed in the HLA-B*52:01−B*67:01− 
Japanese subpopulation (Fig.  5c). The observation that 
Table 3 Amino acid polymorphisms affecting viral replication capacities in the B*5201−/B*6701− population
aa+ sequences containing the amino acid variant in question, aa− sequences lacking the amino acid variant in question




Amino acid  
position
Amino acid RC Sample number Median RC Mann–Whitney U test
Consensus Variant aa+ aa− aa+ aa− P value q value
Gag 79 Matrix F (Y)a Y Lower 147 71 1.10 1.13 0.0081 0.18
218 Capsid V V Higher 58 160 1.13 1.10 0.028 0.26
228 Capsid M L Lower 12 206 1.03 1.11 0.015 0.22
286 Capsid K (R)a R Lower 115 103 1.09 1.13 0.029 0.26
357 Capsid G S Lower 159 59 1.10 1.16 0.0074 0.18
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Gag amino acid variants, at least at position 79 and 
228, are associated with pVL in North America but 
not Japan further supports a lesser role of Gag fitness 
in modulating clinical outcomes in Japan, even in the 
HLA-B*52:01−B*67:01− subpopulation.
Discussion
Mounting evidence suggests the importance of immune 
responses against Gag in the control of HIV-1 infec-
tion [reviewed in 12, 13]. In persons expressing protec-
tive HLA-B*57:01 and B*27:05 alleles, targeting critical 
immunodominant epitopes in Gag slows disease pro-
gression. In vitro viral replication studies, notably those 
using recombinant viruses carrying patient-derived Gag-
Protease sequences, have contributed to this understand-
ing by demonstrating significantly lower Gag-dependent 
viral replication in HIV-1 controllers from North Ameri-
can cohorts [25, 26]. Positive correlations between Gag-
mediated replication capacity and pVL have also been 
reported in HIV-1 subtype C in an African cohort [28, 
29] and subtype B in Mexican and Barbadian cohorts [30] 
which indicated an association between Gag-Pro RC and 
the frequency of protective HLA alleles in the population.
In contrast, our results indicate no significant asso-
ciation of Gag-Pro RC with pVL and CD4 in the over-
all Japanese cohort even though identical experimental 
methods were employed. This lack of significant correla-
tion between Gag-Pro RC and pVL, possibly even in the 
B*52-B*67- subpopulation according to the multivari-
ate analysis, suggests that Gag fitness does not substan-
tially affect pVL in Japan and raises the hypothesis that 
Gag-mediated HIV-1 control is less critical in Japan than 
other populations. The difference could be due to the 
unique HLA distribution in Japan [31], which shapes 
viral diversity at a population level [1]. Particularly, the 
protective HLA-B*57:01 and B*27:05 alleles are virtually 
absent in Japan; instead, HLA-B*52:01 (allele frequency 
10.4–11.1 %) and Asian-specific B*67:01 (allele frequency 
1.1–1.7 %) are associated with HIV-1 control [Allele Fre-
quencies database (http://www.allelefrequencies.net/
default.asp); 32]. Intriguingly, neither B*52:01 nor B*67:01 
was associated with low Gag-Pro RCs, and Gag-Pro RC 
did not correlate with clinical parameters in subjects with 
these protective alleles. As such, we hypothesize that the 
replicative consequences of B*52/B*67-driven immune 
escape mutations in Gag are minimal compared to the 
replicative effects of escape from protective alleles such 
as B*27 and B*57 in other populations. In support of this 
hypothesis, our previous results indicate that the number 
of HLA-associated amino acid changes in Pol, but not in 
Gag, negatively correlate with pVL [31]. The correlation 
was observed in the presence of HLA-B*52:01, suggest-
ing that escape from HLA-B*52:01-restricted responses 
in Pol may confer fitness costs.
The absence of HLA-C*12:02, an allele in tight link-
age disequilibrium with HLA-B*52:01, also showed 
significant associations between RC and both clinical 
parameters. Our previous study demonstrated a negative 
correlation between pVL and B*52:01-associated amino 
acid changes in Pol whereas C*12:02-associated changes 
did not show a significant association [31]. However, the 
effect of B*52:01 cannot be separated in the present study 
due to the extremely low number of B*52:01 or C*12:02 
single positive subjects. The presence of C*08:01 (n = 34) 
and C*08:03 (n =  10) also had strong associations with 
both clinical parameters, but these two alleles are not sig-
nificantly associated with lower or higher pVL in chronic 
phase in our previous study [32]. Therefore, the clini-
cal importance and a putative role of these associations 
require further investigation.
We identified amino acid polymorphisms in Gag that 
were associated with alterations of Gag-Pro RC in the 
absence of protective HLA-B*52:01 and B*67:01 alleles. 
Of the four polymorphisms associated with lower RC, 
one was located in p17 (Y79) and the other three in p24 
(M228, R286, G357). Our previous analysis of HLA-
associated viral polymorphisms in this cohort indicated 
that changes at Y79 were associated with HLA-B*51:01, 
C*14:02, and C*14:03, changes at M228 were associated 
with C*0304, and changes at G357 were associated with 
B*07:02 [31]. Of note, R286 had been previously identi-
fied as B*52:01-associated even though B*52-expressing 
subjects were excluded from the present analysis of RC-
associated substitutions [31]. It is therefore possible that 
R286K imposes a fitness cost in B*52:01+ subjects, but 
Fig. 4 The impact of amino acid polymorphisms in Gag on viral 
fitness. a The x- and y-axes indicate mutation scores and replication 
capacities, respectively. Mutation scores were calculated by giving 
−1 for each polymorphism associated with decreased replication 
capacities in the HLA-B*52:01−B*67:01− subpopulation, i.e. at Gag 79, 
228, 286, and 357, and +1 for a polymorphism at Gag 218, which was 
associated with an increased replication capacity. b Combinations 
of the Gag-Pro RC-decreasing mutations were generated on pNL4-3, 
and their effects on viral replication were investigated in vitro
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its effect on Gag-Pro RC may have been indiscernible 
due to the presence of other RC-modulating mutations 
in these individuals. Moreover, the impact of R286K on 
pVL among B*52:01 individuals may be difficult to detect 
due to two conflicting forces at play: on one hand, R286K 
may slightly lower replication capacity, but on the other 
hand, it confers the ability to escape from CTL responses 
and thus persist in vivo. For B*52:01− subjects, the B*52-
driven R286K immune-escape mutation may have been 
transmitted to B*52:01− recipients, which may have 
Fig. 5 The impact of the amino acid polymorphisms on pVL. The x-axis indicates mutation scores as in Fig. 4. The y-axis represents pVL. Correlations 
between pVL and mutation scores were tested by Spearman’s rank correlation test for the HLA-B*52:01−B*67:01− Japanese (a) and North American 
(b) cohorts described in [18]. c, d The effect of mutations at each position on pVL was examined in the HLA-B*52:01−B*67:01− Japanese (c) and the 
North American (d) populations by the Mann–Whitney U test. The underlined samples indicate the presence of amino acid changes that reduce 
Gag-Pro RC
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resulted in the observed lower Gag-Pro RC (similar to 
the reduced RCs observed when the B*57:01-restricted 
T242N is transmitted to B*57:01− recipients [8, 9] ). Site-
directed mutagenesis confirmed that the four amino acid 
changes significantly reduced Gag-Pro RC. However, the 
reduction in Gag-Pro RCs by these amino acid changes 
did not lead to lower pVL even in the B*52−B*67− sub-
population, suggesting a possible lack of a significant 
impact of Gag fitness on pVL in Japan.
Even though our data argue against a significant role 
of Gag fitness as a major determinant of HIV-1 disease 
outcome in Japan, they do not completely exclude the 
possibility that Gag fitness subtly influences pVL. The 
amino acid changes may have significantly decreased 
pVL, but other mutations in viral genome could have 
restored viral replication capacity in  vivo. These sce-
narios still suggest that pVL does not reflect change in 
Gag fitness, and that Gag replication has only a mini-
mal impact on HIV-1 pathogenesis in Japan. Further 
studies, including longitudinal analyses, will be neces-
sary to identify such compensatory mutations. Alter-
natively, HLA-associated polymorphisms in Gag could 
actually be the result of immune pressure. In this case, a 
high immune pressure in Gag would generate immune-
escape mutations, but the reduction of pVL may have 
occurred through cross-reactive CTL function rather 
than mutation-induced Gag fitness cost. A recent func-
tional study on CTL responses reported 13 epitopes 
(eight in Gag and five in Pol) involved in HIV-1 con-
trol in Japan [39]. B52* and B*67 targeted eight out of 
the 13 epitopes, including seven of the eight epitopes 
located in Gag, suggesting the importance of the Gag 
as an immune target by the Japanese protective alleles 
[39]. Surprisingly, however, only one of the eight dis-
ease-controlling CTL epitopes targeted by B*52 induced 
escape mutations [39]. These results suggest that CTL 
responses directly control pVL by killing infected cells 
via HLA-mediated recognition of Gag epitopes, rather 
than via escape-mediated fitness costs. In addition to 
sustained responses to Gag epitopes that are difficult 
for the virus to escape [39], HLA-mediated protective 
effects in Japan may also be mediated by responses to 
Pol epitopes that eventually induce fitness-costly escape 
mutations within that viral protein, that partially offset 
the advantages gained by escape from CTL responses 
[31].
Gag fitness has an effect on CD4 count in the Japa-
nese population who do not express protective alleles, 
in contrast to global cohorts. At least in this subpopula-
tion, escape mutations in Gag may impose fitness costs 
that are clinically advantageous. However, viral polymor-
phisms that weakly affected pVL did not have an impact 
on Gag fitness even in this B*52−B*67− subpopulation, 
implying a minor contribution of Gag fitness to HIV-1 
clinical outcome. Fitness costs of immune-driven muta-
tions in other viral proteins may have more significant 
impact on HIV-1 disease progression in Japan [31]. These 
observations are in contrast to the previous reports 
which indicated significant correlations between Gag-
Pro RCs and clinical parameters in Mexican/Barbadian 
and African chronic cohorts as well as elite controllers 
and subjects carrying protective HLA alleles in predomi-
nantly Caucasian chronic cohorts [18, 25, 27–30].
Previously, one study analyzed Gag-Pro RC in 156 
treatment-naive Japanese individuals sampled from 
1994 to 2009 and reported reduced Gag-Pro RCs 
among more recent isolates [40]. In contrast to our 
results, they observed a significant association between 
Gag-Pro RC and pVL. The discrepancy between these 
two studies may be due to the characteristics of the 
cohorts and/or study time course. The present study 
analyzed samples collected from 2008 to 2011 whereas 
the previous one focused on older samples. Newer 
viruses may have more chance to accumulate mutations 
that could affect viral replication dependently or inde-
pendently of those occurring in Gag-Protease. Muta-
tions located outside of Gag-Protease could affect pVL 
but not Gag-Pro RCs measured in  vitro, which would 
reduce the correlation between Gag-Pro RC and pVL. 
Sequence comparisons identified significantly differ-
ent amino acid frequencies at 35 out of 500 amino acid 
positions in Gag and eight out of 100 positions in Pol 
between the two cohorts, which may have affected dif-
ferent outcomes in the two cohorts (data not shown). 
In addition, cohort-level differences in HLA prevalence 
(e.g. in the other study, the frequencies of A*24+ and 
C*03+ individuals were 52.6 and 34.6  %, respectively 
whereas the frequencies of these alleles in the present 
study were 62.4 and 42.2 %, respectively) may also have 
affected the results.
Notably, an association between Pol replication 
capacity and HIV-1 disease progression has also 
been reported in North American cohorts [41–46]. 
One of these studies suggested decreased reverse 
transcriptase-integrase-dependent RC in HIV-1 elite 
controllers [41]. In another study B*52:01-associated 
change at amino acid I220 in integrase was shown 
to decrease viral replication capacity [42]. Consid-
ering that Pol enzymatic functions directly affect 
viral replication, mutations in Pol may meaningfully 
impact viral fitness and pVL. Possibly, HLA-associ-
ated HIV-1 polymorphisms in Gag-Protease may not 
affect overall HIV-1 disease outcome in Japan as only 
a few alleles, including HLA-C*08:01 and C*08:03, 
had relatively strong correlations between Gag-Pro 
RC and clinical markers of infection. Additionally, 
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the present study comprised a cross-sectional anal-
ysis at the chronic phase of HIV infection as previ-
ously done in the other global cohort studies except 
for the North American cohort. Thus, we cannot 
exclude a possibility of a significant impact of Gag 
fitness on clinical outcome at different time points: 
e.g. at the acute/early phase. Further study, including 
longitudinal analyses, will be necessary to determine 
a possible role of Gag fitness at the earlier phase as 
well as Pol fitness in HIV-1 disease progression in 
Japan.
Conclusions
Our data support a lack of a significant impact of Gag 
fitness on pVL in treatment-naive Japanese individuals 
chronically infected with HIV-1. Moreover, in contrast 
to non-Asian chronic cohorts where Gag-Pro RC fit-
ness may modulate HIV clinical parameters especially 
in subjects with protective HLA alleles, the protective 
effects of Japanese B*52 and B*67 alleles do not seem 
to be associated with Gag fitness. Thus, the impact of 




A total of 430 treatment-naive Japanese subjects chroni-
cally infected with HIV-1 subtype B were recruited for a 
previous study [31] and enrolled at the National Center 
for Global Health and Medicine (NCGHM) from 2008 
to 2011. HLA typing and the preparation of cDNA sam-
ples from patient plasma were performed as described 
in the previous study. For the present study, specimens 
from 306 of the original 430 participants were randomly 
selected for analysis. The median pVL and CD4 count for 
this N = 306 cohort were 4.5 log10 RNA copies/ml (IQR: 
4.1–5.1) and 299 cells/mm3 (IQR: 151–407), respectively. 
The study was approved by the Ethical Committees in the 
Faculty of Life Science, Kumamoto University and the 
NCGHM and conducted in accordance with the Declara-
tion of Helsinki.
For comparison with the Japanese cohort, a data set 
derived from a published North American (Canada and 
USA) cohort comprising 803 untreated chronic subjects 
infected with HIV-1 subtype B was used for the analysis 
[18]. Median pVL and CD4 count for the cohort were 5.1 
log10 RNA copies/ml (IQR: 4.7–5.5) and 273  cells/mm3 
(IQR: 130–420), respectively [18].
Generation of chimeric viruses and in vitro replication 
assays
The production of chimeric viruses and Gag-Pro RC 
determination was performed as described previously 
[18, 25–30]. Briefly, cDNAs were generated from plasma 
viral RNA for a separate study [31]. Plasma-derived 
gag-protease DNA fragments were generated from the 
cDNAs by nested PCR, using TaKaRa ExTaq Hot Start 
Version (Takara Bio Inc., Shiga, Japan). Chimeric HIV-
1NL4-3 encoding plasma-derived gag-protease was gener-
ated by electroporating gag-protease PCR fragments with 
linearized gag-protease-deficient pNL4-3 (delta gag-pro 
NL4-3) into a CEM-derived GFP-reporter T-cell line 
engineered to carry LTR-GFP, CXCR4, and CCR5 (CEM-
GXR, a generous gift from T. Miura and M.A. Brock-
man) [38] . Stock titers were determined by infecting 
CEM-GXR and measuring GFP+ cells, using flow cytom-
etry. To determine Gag-Pro RCs, CEM-GXR cells were 
infected with chimeric viruses at a MOI of 0.03 at day 
2, and the percentage of HIV-infected (GFP-expressing) 
cells was monitored daily for 2–8  days post-infection. 
Gag-Pro RC was calculated as the natural-log slope of 
the percentage of GFP-expressing cells during the expo-
nential phase of viral spread and normalized against the 
mean value obtained with wild-type NL4-3 (i.e. NL4-3 
RC  =  1.00). Virus titration and RC experiments were 
done in triplicate.
For the validation of virus stocks, we isolated RNA 
from all virus stocks, using EZ1 Virus Mini Kit v2.0 (Qia-
gen, Valencia, CA). Gag-protease DNA fragments were 
generated by RT-PCR, using SuperScript III First-Strand 
Synthesis System for RT-PCR (Life Technologies, Carls-
bad, CA) for cDNA synthesis and TaKaRa ExTaq Hot 
Start Version for subsequent nested PCR. Viral sequences 
were analyzed on the ABI3500 genetic analyzer (Applied 
Biosystems, Carlsbad, CA) and compared with previ-
ously determined gag-protease sequences from patients’ 
plasma viruses [31] by constructing a maximum-likeli-
hood phylogenetic tree (PhyML) [47]. Phylogenies were 
viewed using Figtree (http://tree.bio.ed.ac.uk/software/
figtree).
Definition and analysis of HLA‑associated polymorphisms 
in Gag‑Protease
A total of 110 HLA-associated polymorphisms, occur-
ring at 61 unique codons in Gag-Protease, were previ-
ously defined in a cohort of 430 treatment-naive Japanese 
subjects using phylogenetically-corrected methods [31]. 
In the present study we wished to identify HLA-asso-
ciated polymorphisms that modulate Gag-Pro RC. For 
this purpose, we compared Gag-Pro RCs in the presence 
or absence of each of these HLA-associated amino acid 
substitutions and assessed significance using the Mann–
Whitney U test. Figures depicting amino acid variation 
at Gag-Pro-RC-modulating codons were created using 
WebLogo 3 (http://weblogo.threeplusone.com) [48, 49] 
to visualize sequence conservation at each position.
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Site‑directed mutagenesis and mutant virus stocks
Y79F, M228, and R286K substitutions were engineered 
into HIV-1 pNL4-3 by PCR overlap extension [50, 
51], using PCR primers containing specific nucleotide 
changes: tat to ttc for Y79F, atg to ctg for M228L and 
aga to aag for R286K. These specific triplet codons 
were selected for each substitution based on higher 
frequencies in human codon usage, to exclude possi-
ble negative effects of rare codon usage in  vitro. PCR 
fragments containing specific nucleotide changes were 
digested with BssHII (at nucleotide position 711 in 
pNL4-3) and SbfI (at 2838 in pNL4-3) followed by sub-
cloning into pNL4-3 digested with the same restriction 
enzymes. The subcloned fragments were sequenced to 
confirm specific nucleotide changes and the absence of 
other mutations.
pNL4-3 carrying specific mutations were transfected 
into HEK293T cells by lipofectamine 2000 (Life Tech-
nologies, Carlsbad, CA) according to the manufac-
turer’s instructions. Virus stocks were harvested 48  h 
post-transfection, and titers were determined by infect-
ing CEM-GXR cells and subsequently measuring GFP+ 
cells. Replication assays were performed in two sets of 
triplicate for each sample as described above.
Statistical analysis
Associations between Gag-Pro RC, clinical parameters 
and mutation scores were determined by Spearman’s 
rank correlation. Differences in pVL in context of the 
presence or absence of amino acid substitutions at four 
locations in Gag were determined by the Mann–Whit-
ney U test. Multiple comparisons were addressed using 
q-values.
The relationship between Gag-Pro RC and pVL/CD4 
count in the population subset that did not express 
protective HLA class I alleles (HLA-B*52:01−B*67:01− 
subset) was also investigated using multivariable lin-
ear regression. The primary model included only log10 
plasma viral load (per log10 increment) and CD4 count 
(per 1 cell/mm3 increment) as variables. A second model 
additionally incorporated specific HLA alleles (C*08:01, 
C*08:02, C*12:02) that exhibited significant associations 
between Gag-Pro RC and both pVL and CD4 count as 
variables; here, model estimates are expressed in terms of 
individuals harboring (versus the reference group of indi-
viduals not harboring) the HLA allele in question. Multi-
variable analyses were performed using R (version 3.1.2).
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quartile range (box) were indicated. The black vertical lines indicate the 
median RC for the whole population (N = 298). HLA alleles were arranged 
from lowest (top) to highest (bottom) by their mean replication capacities. 
(D) The relationship between median Gag-Pro RCs and median pVL. Cor-
relations were examined by Spearman’s rank correlation test. Each circle 
represents median Gag-Pro RC and pVL for a group of subjects expressing 
one of the HLA alleles.
Additional file 3: Table S1. Associations of Gag-Pro RCs with 
clinical parameters in each HLA-class-I allele in the absence of 
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on the HIV-1 HXB2 strain. Consensus amino acids are indicated on the left 
and mutations on the right of each logo. Hydrophilic residues (RKDNQ) 
were shown in blue, neutral residues (SGHTAP) in green, and hydrophobic 
residues (YVMCLFIW) in black.
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